Report Detail

Request for Sample of this report

Other Global Peptide Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4657367
    • |
  • 06 March, 2026
    • |
  • Global
    • |
  • 121 Pages
    • |
  • GIR
    • |
  • Other

According to our (Global Info Research) latest study, the global Peptide Therapeutics market size was valued at US$ 45600 million in 2025 and is forecast to a readjusted size of US$ 81710 million by 2032 with a CAGR of 8.8% during review period.
Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.The average gross profit margin of this product is 70%.
The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.
Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.
This report is a detailed and comprehensive analysis for global Peptide Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Peptide Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Peptide Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Peptide Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Peptide Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Peptide Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Peptide Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie, Ipsen, Ferring, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Peptide Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Injection
Oral
Other
Market segment by Target Class
Agonist/Analog
Antagonist
Enzyme Inhibitor
Ion Channel
Market segment by End Users
Retail
Hospital
Other
Market segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
Market segment by players, this report covers
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Aurinia Pharmaceuticals
BioMarin Pharmaceutical
Apellis Pharmaceuticals
Lantheus
CSL Vifor Group
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Peptide Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Peptide Therapeutics, with revenue, gross margin, and global market share of Peptide Therapeutics from 2021 to 2026.
Chapter 3, the Peptide Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Peptide Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide Therapeutics.
Chapter 13, to describe Peptide Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Peptide Therapeutics by Type
    • 1.3.1 Overview: Global Peptide Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Peptide Therapeutics Consumption Value Market Share by Type in 2025
    • 1.3.3 Injection
    • 1.3.4 Oral
    • 1.3.5 Other
  • 1.4 Classification of Peptide Therapeutics by Target Class
    • 1.4.1 Overview: Global Peptide Therapeutics Market Size by Target Class: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Peptide Therapeutics Consumption Value Market Share by Target Class in 2025
    • 1.4.3 Agonist/Analog
    • 1.4.4 Antagonist
    • 1.4.5 Enzyme Inhibitor
    • 1.4.6 Ion Channel
  • 1.5 Classification of Peptide Therapeutics by End Users
    • 1.5.1 Overview: Global Peptide Therapeutics Market Size by End Users: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Peptide Therapeutics Consumption Value Market Share by End Users in 2025
    • 1.5.3 Retail
    • 1.5.4 Hospital
    • 1.5.5 Other
  • 1.6 Global Peptide Therapeutics Market by Application
    • 1.6.1 Overview: Global Peptide Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Cancer
    • 1.6.3 Metabolic Disorders
    • 1.6.4 Central Nervous System
    • 1.6.5 Other
  • 1.7 Global Peptide Therapeutics Market Size & Forecast
  • 1.8 Global Peptide Therapeutics Market Size and Forecast by Region
    • 1.8.1 Global Peptide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Peptide Therapeutics Market Size by Region, (2021-2032)
    • 1.8.3 North America Peptide Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Peptide Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Peptide Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.6 South America Peptide Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Peptide Therapeutics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Sanofi
    • 2.1.1 Sanofi Details
    • 2.1.2 Sanofi Major Business
    • 2.1.3 Sanofi Peptide Therapeutics Product and Solutions
    • 2.1.4 Sanofi Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Sanofi Recent Developments and Future Plans
  • 2.2 Teva
    • 2.2.1 Teva Details
    • 2.2.2 Teva Major Business
    • 2.2.3 Teva Peptide Therapeutics Product and Solutions
    • 2.2.4 Teva Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Teva Recent Developments and Future Plans
  • 2.3 Novo Nordisk
    • 2.3.1 Novo Nordisk Details
    • 2.3.2 Novo Nordisk Major Business
    • 2.3.3 Novo Nordisk Peptide Therapeutics Product and Solutions
    • 2.3.4 Novo Nordisk Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Novo Nordisk Recent Developments and Future Plans
  • 2.4 Takeda
    • 2.4.1 Takeda Details
    • 2.4.2 Takeda Major Business
    • 2.4.3 Takeda Peptide Therapeutics Product and Solutions
    • 2.4.4 Takeda Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Takeda Recent Developments and Future Plans
  • 2.5 Eli Lilly
    • 2.5.1 Eli Lilly Details
    • 2.5.2 Eli Lilly Major Business
    • 2.5.3 Eli Lilly Peptide Therapeutics Product and Solutions
    • 2.5.4 Eli Lilly Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Eli Lilly Recent Developments and Future Plans
  • 2.6 AstraZeneca
    • 2.6.1 AstraZeneca Details
    • 2.6.2 AstraZeneca Major Business
    • 2.6.3 AstraZeneca Peptide Therapeutics Product and Solutions
    • 2.6.4 AstraZeneca Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 AstraZeneca Recent Developments and Future Plans
  • 2.7 Novartis
    • 2.7.1 Novartis Details
    • 2.7.2 Novartis Major Business
    • 2.7.3 Novartis Peptide Therapeutics Product and Solutions
    • 2.7.4 Novartis Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Novartis Recent Developments and Future Plans
  • 2.8 AbbVie
    • 2.8.1 AbbVie Details
    • 2.8.2 AbbVie Major Business
    • 2.8.3 AbbVie Peptide Therapeutics Product and Solutions
    • 2.8.4 AbbVie Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 AbbVie Recent Developments and Future Plans
  • 2.9 Ipsen
    • 2.9.1 Ipsen Details
    • 2.9.2 Ipsen Major Business
    • 2.9.3 Ipsen Peptide Therapeutics Product and Solutions
    • 2.9.4 Ipsen Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Ipsen Recent Developments and Future Plans
  • 2.10 Ferring
    • 2.10.1 Ferring Details
    • 2.10.2 Ferring Major Business
    • 2.10.3 Ferring Peptide Therapeutics Product and Solutions
    • 2.10.4 Ferring Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Ferring Recent Developments and Future Plans
  • 2.11 Merck
    • 2.11.1 Merck Details
    • 2.11.2 Merck Major Business
    • 2.11.3 Merck Peptide Therapeutics Product and Solutions
    • 2.11.4 Merck Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Merck Recent Developments and Future Plans
  • 2.12 The Medicines
    • 2.12.1 The Medicines Details
    • 2.12.2 The Medicines Major Business
    • 2.12.3 The Medicines Peptide Therapeutics Product and Solutions
    • 2.12.4 The Medicines Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 The Medicines Recent Developments and Future Plans
  • 2.13 J & J
    • 2.13.1 J & J Details
    • 2.13.2 J & J Major Business
    • 2.13.3 J & J Peptide Therapeutics Product and Solutions
    • 2.13.4 J & J Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 J & J Recent Developments and Future Plans
  • 2.14 Aurinia Pharmaceuticals
    • 2.14.1 Aurinia Pharmaceuticals Details
    • 2.14.2 Aurinia Pharmaceuticals Major Business
    • 2.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Product and Solutions
    • 2.14.4 Aurinia Pharmaceuticals Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Aurinia Pharmaceuticals Recent Developments and Future Plans
  • 2.15 BioMarin Pharmaceutical
    • 2.15.1 BioMarin Pharmaceutical Details
    • 2.15.2 BioMarin Pharmaceutical Major Business
    • 2.15.3 BioMarin Pharmaceutical Peptide Therapeutics Product and Solutions
    • 2.15.4 BioMarin Pharmaceutical Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 BioMarin Pharmaceutical Recent Developments and Future Plans
  • 2.16 Apellis Pharmaceuticals
    • 2.16.1 Apellis Pharmaceuticals Details
    • 2.16.2 Apellis Pharmaceuticals Major Business
    • 2.16.3 Apellis Pharmaceuticals Peptide Therapeutics Product and Solutions
    • 2.16.4 Apellis Pharmaceuticals Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Apellis Pharmaceuticals Recent Developments and Future Plans
  • 2.17 Lantheus
    • 2.17.1 Lantheus Details
    • 2.17.2 Lantheus Major Business
    • 2.17.3 Lantheus Peptide Therapeutics Product and Solutions
    • 2.17.4 Lantheus Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Lantheus Recent Developments and Future Plans
  • 2.18 CSL Vifor Group
    • 2.18.1 CSL Vifor Group Details
    • 2.18.2 CSL Vifor Group Major Business
    • 2.18.3 CSL Vifor Group Peptide Therapeutics Product and Solutions
    • 2.18.4 CSL Vifor Group Peptide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 CSL Vifor Group Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Peptide Therapeutics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Peptide Therapeutics by Company Revenue
    • 3.2.2 Top 3 Peptide Therapeutics Players Market Share in 2025
    • 3.2.3 Top 6 Peptide Therapeutics Players Market Share in 2025
  • 3.3 Peptide Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Peptide Therapeutics Market: Region Footprint
    • 3.3.2 Peptide Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Peptide Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Peptide Therapeutics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Peptide Therapeutics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Peptide Therapeutics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Peptide Therapeutics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Peptide Therapeutics Consumption Value by Type (2021-2032)
  • 6.2 North America Peptide Therapeutics Market Size by Application (2021-2032)
  • 6.3 North America Peptide Therapeutics Market Size by Country
    • 6.3.1 North America Peptide Therapeutics Consumption Value by Country (2021-2032)
    • 6.3.2 United States Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Peptide Therapeutics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Peptide Therapeutics Consumption Value by Type (2021-2032)
  • 7.2 Europe Peptide Therapeutics Consumption Value by Application (2021-2032)
  • 7.3 Europe Peptide Therapeutics Market Size by Country
    • 7.3.1 Europe Peptide Therapeutics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.3 France Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Peptide Therapeutics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Peptide Therapeutics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Peptide Therapeutics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Peptide Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Peptide Therapeutics Consumption Value by Region (2021-2032)
    • 8.3.2 China Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.5 India Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Peptide Therapeutics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Peptide Therapeutics Consumption Value by Type (2021-2032)
  • 9.2 South America Peptide Therapeutics Consumption Value by Application (2021-2032)
  • 9.3 South America Peptide Therapeutics Market Size by Country
    • 9.3.1 South America Peptide Therapeutics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Peptide Therapeutics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Peptide Therapeutics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Peptide Therapeutics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Peptide Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Peptide Therapeutics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Peptide Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Peptide Therapeutics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Peptide Therapeutics Market Drivers
  • 11.2 Peptide Therapeutics Market Restraints
  • 11.3 Peptide Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Peptide Therapeutics Industry Chain
  • 12.2 Peptide Therapeutics Upstream Analysis
  • 12.3 Peptide Therapeutics Midstream Analysis
  • 12.4 Peptide Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Peptide Therapeutics. Industry analysis & Market Report on Peptide Therapeutics is a syndicated market report, published as Global Peptide Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Peptide Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo